U.S. markets open in 29 minutes
  • S&P Futures

    3,435.75
    +3.50 (+0.10%)
     
  • Dow Futures

    28,187.00
    +5.00 (+0.02%)
     
  • Nasdaq Futures

    11,671.75
    +11.00 (+0.09%)
     
  • Russell 2000 Futures

    1,614.30
    -0.50 (-0.03%)
     
  • Crude Oil

    41.14
    -0.56 (-1.34%)
     
  • Gold

    1,928.30
    +12.90 (+0.67%)
     
  • Silver

    25.27
    +0.30 (+1.18%)
     
  • EUR/USD

    1.1867
    +0.0038 (+0.32%)
     
  • 10-Yr Bond

    0.8130
    +0.0160 (+2.01%)
     
  • Vix

    29.70
    +0.52 (+1.78%)
     
  • GBP/USD

    1.3096
    +0.0149 (+1.15%)
     
  • USD/JPY

    104.5850
    -0.8850 (-0.84%)
     
  • BTC-USD

    12,421.21
    +1,364.20 (+12.34%)
     
  • CMC Crypto 200

    248.87
    +9.95 (+4.16%)
     
  • FTSE 100

    5,811.65
    -77.57 (-1.32%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

AstraZeneca citizen petitions on Quetiapine labeling receives FDA response

AstraZeneca announced that on March 7, the FDA denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL, or quetiapine fumarate, tablets and SEROQUEL XR extended-release tablets. AstraZeneca is evaluating the FDA’s decision and reasoning.